Cabbacis Granted U.S. Patent for Vaporizer Pods

*NIAGARA FALLS, N.Y. —* The United States Patent and Trademark Office has
issued a patent to Cabbacis for vaporizer pods for oral electronic
vaporizers.

U.S. Patent No. 12,349,724, which expires on July 27, 2038, includes ten
claims on pods for electronic vaporizers. The claims cover vaporizer pods
comprising blends of at least 5 mg of conventional-nicotine reconstituted
tobacco and at least 5 mg of hemp, and separately, at least 5 mg of
reduced-nicotine reconstituted tobacco and at least 5 mg of hemp.
Reconstituted tobacco is typically used in closed-end electronic vaporizer
pods. Commercial examples of popular, closed-end electronic vaporizers –
also known as heat-not-burn products – include IQOS, Ploom, and glo.

Vaporizer pods covered under the 724 patent that contain
conventional-nicotine tobacco and hemp will provide consumers with pleasant
and differentiated taste and sensory characteristics, as compared to the
above vaporizer brands that contain conventional-nicotine tobacco without
any hemp.

Cabbacis owns two other previously-issued U.S. patents on vaporizer pods
containing tobacco and hemp: 10,777,091 and 10,973,255 along with various
international vaporizer pod patents.

The Company’s patented, reduced-nicotine, iBlend vaporizer pods and
patented, reduced-nicotine, iBlend cigarettes in development are to assist
vapers or smokers of conventional tobacco products to vape or smoke less or
transition to less harmful tobacco or nicotine products. iBlend
reduced-nicotine cigarettes contain approximately 95 percent less nicotine
than conventional cigarette brands. The Company’s products in development
are patented in many of the largest tobacco markets across the globe
including the United States, China, Europe, Brazil, and Japan.

Joseph Pandolfino, Chief Executive Officer of Cabbacis, commented, “We are
thrilled to announce this new patent for vaporizer pods, further fortifying
our already robust intellectual property position. This patent, when taken
in tandem with our existing patents, comprehensively cover, across more
than 30 countries, any ratio of reduced-nicotine tobacco and hemp blended
together in cigarettes and/or any ratio of conventional-nicotine tobacco
and hemp or reduced-nicotine tobacco and hemp blended together in vaporizer
products.”
About Cabbacis

Cabbacis (OTCQB: CABI) is committed to commercializing groundbreaking
tobacco harm-reduction products in the global tobacco market for the
world’s one billion smokers with its flagship iBlend reduced-nicotine
cigarettes and vaporizer pods in development. The worldwide patent
portfolio of Cabbacis LLC includes 35 issued patents and various pending
patent applications across the United States, Europe, China, India, Japan,
Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico,
Brazil, and other countries – where approximately two-thirds of the world’s
smokers reside. Cabbacis holds 7 U.S. patents. Cabbacis LLC is a
wholly-owned subsidiary of Cabbacis Inc.